达芦那韦/利托那韦低剂量单药治疗维持HIV病毒学抑制
这项单中心观察性48周研究纳入31例已抑制HIV病毒血症的患者,换用达芦那韦/利托那韦600/100 mg每日一次单药治疗。第24周病毒学成功率为100%(95%CI 89-100),无病毒学失败,2例因副作用停药。低剂量单药治疗在病毒学抑制患者中高效。
要点
- 低剂量达芦那韦/利托那韦600/100 mg每日一次单药治疗维持病毒学抑制有效。
- 第24周和第48周病毒学抑制率均为100%(95%CI 89-100),无病毒学失败。
- 治疗策略成功率第24周96.8%,第48周93.5%,2例因副作用停药。
核心结论
- 低剂量达芦那韦/利托那韦600/100 mg每日一次单药治疗在病毒学抑制的HIV感染者中高度有效。
- 需进一步研究确认这些数据。
研究设计与样本
- 单中心观察性48周研究,纳入2013至2015年间换用达芦那韦/利托那韦600/100 mg每日一次单药治疗的HIV病毒学抑制患者31例。
主要发现
- 31例患者基线中位年龄52岁,CD4+计数649 cells/mm3,ART疗程16.3年,CD4+最低值195 cells/mm3,HIV抑制持续时间7.8年。
- 换药前28/31例接受PI单药治疗(达芦那韦/利托那韦800/100 mg每日一次26例,洛匹那韦/利托那韦1例,阿扎那韦/利托那韦1例),3/31例接受三药方案。
- 48周随访期间无病毒学失败,2例因副作用停药(第16周和第40周),第24周和第48周病毒学抑制率均为100%(95%CI 89-100)。
- 治疗策略成功率第24周为96.8%(95%CI 83.3-99.9),第48周为93.5%(95%CI 78.6-99.2)。
- 达芦那韦/利托那韦800/100 mg和600/100 mg的中位Ctrough分别为1537 ng/mL(IQR 1286-1724)和1255 ng/mL(IQR 873-2161)。
关键数值与推荐
- 病毒学成功定义为血浆病毒载量<50 copies/mL。
- 主要结局为第24周病毒学成功比例,次要结局包括治疗策略成功和耐药。
临床怎么用
- 对于已实现病毒学抑制且适合单药治疗的HIV感染者,可考虑达芦那韦/利托那韦600/100 mg每日一次作为维持方案。
- 治疗期间需监测副作用,本研究中有2例因副作用停药。
局限性
- 单中心观察性研究,样本量小(31例)。
- 需进一步研究确认低剂量单药治疗的数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Darunavir/ritonavir is a potent PI with a high genetic barrier and pharmacological robustness favourably investigated as monotherapy. Whether darunavir could be dose reduced in the context of monotherapy deserves investigation. METHODS: Patients with HIV suppressed viraemia (plasma viral load <50 copies/mL for 12 months) under ART who had switched to darunavir/ritonavir monotherapy at 600/100 mg/day between 2013 and 2015 were included in this observational 48 week single-centre study. The primary outcome was the proportion of patients with virological success (defined as plasma viral load <50 copies/mL) at week 24. Secondary outcomes included treatment strategy success and resistance. RESULTS: Thirty-one patients were included with the following baseline characteristics [median (IQR)]: age 52 years (47-57), CD4+ 649 cells/mm3 (463-813), ART duration 16.3 years (9.2-22.3), nadir CD4+ 195 cells/mm3 (144-261) and duration of HIV suppression 7.8 years (4.8-9.7). Prior to switch, ART consisted of PI monotherapy for 28 of 31 patients [darunavir/ritonavir 800/100 mg/day (n = 26), lopinavir/ritonavir (n = 1) and atazanavir/ritonavir (n = 1)] and a triple drug regimen for 3 of 31 patients. Within the 48 weeks of follow-up, no virological failure occurred and two patients discontinued 600/100 mg of darunavir/ritonavir due to side effects at week 16 and 40, leading to a virological suppression rate of 100% (95% CI = 89-100) at weeks 24 and 48. Strategy success rates were 96.8% (95% CI = 83.3-99.9) at week 24 and 93.5% (95% CI = 78.6-99.2) at week 48. Median (IQR) Ctrough values of 800/100 mg of darunavir/ritonavir and 600/100 mg of darunavir/ritonavir were 1537 ng/mL (1286-1724) and 1255 ng/mL (873-2161), respectively. CONCLUSIONS: A lower dose of darunavir/ritonavir used as monotherapy (600/100 mg/day) was highly effective in virologically suppressed HIV-infected patients. Further studies are needed to confirm these data.
引用
- Seang S, Schneider L, Nguyen T, et al. Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia. J Antimicrob Chemother. 2018. PMID: 29216346. doi:10.1093/jac/dkx417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。